Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults
Primary Purpose
Influenza
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
H1N1 influenza A Vaccine (PANFLU.1)
Trivalent Inactivated Influenza Vaccine (ANFLU)
Sponsored by
About this trial
This is an interventional prevention trial for Influenza
Eligibility Criteria
Inclusion Criteria:
- Healthy male or female aged between 18 and 60
- Be able to show legal identity card for the sake of recruitment
- Volunteers are able to understand and sign the informed consent
Exclusion Criteria:
- Cases, cured cases and close contact of influenza A (H1N1) virus
- History of H1N1 vaccine or seasonal influenza vaccine administration
- Women of pregnancy, lactation or about to be pregnant in 60 days
- Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Autoimmune disease or immunodeficiency
- Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- Diabetes mellitus (type I or II), with the exception of gestational diabetes
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
Seizure disorder other than:
- Febrile seizures under the age of two years old
- Seizures secondary to alcohol withdrawal more than 3 years ago, or
- A singular seizure not requiring treatment within the last 3 years
- Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
- Guillain-Barre Syndrome
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products within 3 months before the dosing
- Administration of any other investigational research agents within 30 days before the dosing
- Administration of any live attenuated vaccine within 30 days before the dosing
- Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
- Be receiving anti-TB prophylaxis or therapy currently
- Axillary temperature > 37.0 centigrade at the time of dosing
Psychiatric condition that precludes compliance with the protocol:
- Past or present psychoses
- Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
- Disorder requiring lithium
- Suicidal ideation occurring within five years prior to enrollment
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Sites / Locations
- Beijing Centers for Diseases Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Group 1: Day 0-PANFLU.1; Day 21-ANFLU
Group 2: Day 0-ANFLU; Day 21-PANFLU.1
Group 3: Day 0-PANFLU.1+ANFLU
Arm Description
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
Outcomes
Primary Outcome Measures
Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine
Secondary Outcome Measures
Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults
Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults
Full Information
NCT ID
NCT01008137
First Posted
October 29, 2009
Last Updated
November 26, 2012
Sponsor
Sinovac Biotech Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT01008137
Brief Title
Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults
Official Title
Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults
Study Type
Interventional
2. Study Status
Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
January 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd
4. Oversight
5. Study Description
Brief Summary
A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Care Provider
Allocation
Randomized
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1: Day 0-PANFLU.1; Day 21-ANFLU
Arm Type
Experimental
Arm Description
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
Arm Title
Group 2: Day 0-ANFLU; Day 21-PANFLU.1
Arm Type
Experimental
Arm Description
50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
Arm Title
Group 3: Day 0-PANFLU.1+ANFLU
Arm Type
Experimental
Arm Description
50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
Intervention Type
Biological
Intervention Name(s)
H1N1 influenza A Vaccine (PANFLU.1)
Intervention Description
H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
Intervention Type
Biological
Intervention Name(s)
Trivalent Inactivated Influenza Vaccine (ANFLU)
Intervention Description
Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Primary Outcome Measure Information:
Title
Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults
Time Frame
3 months
Title
Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male or female aged between 18 and 60
Be able to show legal identity card for the sake of recruitment
Volunteers are able to understand and sign the informed consent
Exclusion Criteria:
Cases, cured cases and close contact of influenza A (H1N1) virus
History of H1N1 vaccine or seasonal influenza vaccine administration
Women of pregnancy, lactation or about to be pregnant in 60 days
Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
Autoimmune disease or immunodeficiency
Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
Diabetes mellitus (type I or II), with the exception of gestational diabetes
History of thyroidectomy or thyroid disease that required medication within the past 12 months
Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
Seizure disorder other than:
Febrile seizures under the age of two years old
Seizures secondary to alcohol withdrawal more than 3 years ago, or
A singular seizure not requiring treatment within the last 3 years
Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
Guillain-Barre Syndrome
Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
History of any blood products within 3 months before the dosing
Administration of any other investigational research agents within 30 days before the dosing
Administration of any live attenuated vaccine within 30 days before the dosing
Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
Be receiving anti-TB prophylaxis or therapy currently
Axillary temperature > 37.0 centigrade at the time of dosing
Psychiatric condition that precludes compliance with the protocol:
Past or present psychoses
Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
Disorder requiring lithium
Suicidal ideation occurring within five years prior to enrollment
Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Facility Information:
Facility Name
Beijing Centers for Diseases Control and Prevention
City
Beijing
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
21130194
Citation
Wu J, Zhong X, Li CK, Zhou JF, Lu M, Huang KY, Dong M, Liu Y, Luo FJ, Du N, Chui C, Liu LQ, Smith NM, Li B, Shi NM, Song LF, Gao Y, Wang DY, Wang X, Zhu WF, Yan Y, Li Z, Chen JT, McMichael AJ, Yin WD, Xu XN, Shu Y. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine. 2011 Jan 29;29(5):1009-16. doi: 10.1016/j.vaccine.2010.11.058. Epub 2010 Dec 2.
Results Reference
derived
Learn more about this trial
Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults
We'll reach out to this number within 24 hrs